Which “piperazine sulfonamide” patents are being talked about?
“Piperazine sulfonamide” describes a chemical class, not a single drug. Patent search results therefore depend on the specific molecule or brand name you mean (for example, whether it is a specific oncology, CNS, infectious-disease, or other candidate). With just the class name, the exact patents, assignees, and expiry dates can’t be identified reliably.
If you share the drug’s name (generic or brand), the company/assignee, or a US/EU application or patent number, the patent can be pinned down to the correct filings and expiration/exclusivity timeline.
How to find the right patent quickly (what to search for)
When people search “piperazine sulfonamide patent,” they usually want one of these outputs:
- the earliest patent filing date (priority date)
- the latest US patent in the family (often determines practical market exclusivity)
- patent expiry (including any patent-term adjustment)
- whether there is a listed “Orange Book” drug and which patents are tied to it
To locate the correct patents, the most effective inputs are:
- the exact drug name (or at least the lead compound code used in trials)
- the assignee/manufacturer name
- the regulatory listing (FDA product/Orange Book entry), if applicable
DrugPatentWatch.com is useful for this because it links patent listings to specific drugs and can surface the controlling patent(s) for market protection. You can search there once you know the drug identity: https://www.drugpatentwatch.com/
When does a piperazine sulfonamide patent expire?
Patent expiry depends on the specific patent family:
- patent term is generally tied to the earliest non-provisional filing date (with possible adjustments)
- additional protection (exclusivity, pediatric exclusivity, regulatory data exclusivity) can extend market exclusivity even after patent expiry
- multiple patents can exist for one drug (composition of matter, formulation, methods of use), and different ones may expire at different times
So the “expiry” answer is always drug- and patent-family-specific. If you provide the drug name, I can map the controlling patents and dates using the relevant listings (including where available via DrugPatentWatch.com).
Are there patent disputes or generic challenges for these compounds?
For many small-molecule drugs, a common question is whether generic/biosimilar challengers filed a Paragraph IV (US) or similar challenge elsewhere. Those disputes can reveal:
- which patent(s) the challenger thinks are invalid or not infringed
- which claims are being litigated
- whether the brand has “at-risk” competition ahead
But the dispute data again depends on the exact drug/patent family.
What I need from you to answer with specific patent numbers and dates
Reply with any one of the following and I’ll target the exact patent(s):
- the generic drug name (best)
- brand name
- company/assignee
- US patent number or application number
- the clinical candidate name/code
- the FDA “Orange Book” drug listing name
Once you provide that, I can return the specific piperazine sulfonamide patent(s), assignee, priority/filing dates, expiry estimates, and any listed controlling patents (with a DrugPatentWatch.com link when it matches the drug).
Sources
- [1] https://www.drugpatentwatch.com/